|Articles|May 17, 2022

VIDA Expands Site Network

VIDA has onboarded more than 1,000 sites globally in its network of imaging sites.

VIDA Diagnostics, Inc. has onboarded more than 1,000 sites globally in its VIDA network of imaging sites. This network is connected through the VIDA Intelligence Portal, a cloud native AI-enabled platform that drives efficiencies in clinical trial imaging operations by optimizing site recruitment and onboarding, staff training, image data collection, data quality, data curation, and more.

Read more about the site network here.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related Articles

Merck Reports Strong Phase II Results for Ifinatamab Deruxtecan in Extensive-Stage Small Cell Lung Cancer
September 15th 2025
ACT Brief Weekly Recap: How AI, eClinical Innovation, and Policy Shifts Are Reshaping Clinical Research
September 15th 2025
Phase IV Trial Shows Daybue Demonstrates Real-World Behavioral Improvements in Rett Syndrome
September 15th 2025
Capvaxive Demonstrates Robust Immune Responses in Children, Adolescents at Increased Risk of Pneumococcal Disease
September 15th 2025
NIMBLE Trial Reveals New Insights on Complement Inhibition in gMG
September 15th 2025
Q&A: Strategies for Successful Global Clinical Trial Delivery
September 12th 2025

Trending on Applied Clinical Trials Online

Capvaxive Demonstrates Robust Immune Responses in Children, Adolescents at Increased Risk of Pneumococcal Disease

NIMBLE Trial Reveals New Insights on Complement Inhibition in gMG

ACT Brief Weekly Recap: How AI, eClinical Innovation, and Policy Shifts Are Reshaping Clinical Research

Phase IV Trial Shows Daybue Demonstrates Real-World Behavioral Improvements in Rett Syndrome

© 2025 MJH Life Sciences^®

All rights reserved.